title: Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
abstract: Veltuzumab is a humanized anti-CD20 monoclonal antibody with complementarity-determining regions (CDRs) identical to rituximab, except for one residue at the 101st position (Kabat numbering) in CDR3 of the variable heavy chain (V(H)), having aspartic acid (Asp) instead of asparagine (Asn), with framework regions of epratuzumab, a humanized anti-CD22 antibody. When compared with rituximab, veltuzumab has significantly reduced off-rates in 3 human lymphoma cell lines tested, as well as increased complement-dependent cytotoxicity in 1 of 3 cell lines, but no other in vitro differences. Mutation studies confirmed that the differentiation of the off-rate between veltuzumab and rituximab is related to the single amino acid change in CDR3-V(H). Studies of intraperitoneal and subcutaneous doses in mouse models of human lymphoma and in normal cynomolgus monkeys disclosed that low doses of veltuzumab control tumor growth or deplete circulating or sessile B cells. Low- and high-dose veltuzumab were significantly more effective in vivo than rituximab in 3 lymphoma models. These findings are consistent with activity in patients with non-Hodgkin lymphoma given low intravenous or subcutaneous doses of veltuzumab. Thus, changing Asn(101) to Asp(101) in CDR3-V(H) of rituximab is responsible for veltuzumab's lower off-rate and apparent improved potency in preclinical models that could translate into advantages in patients.
authors.affiliation: Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA. dmg.gscancer@att.net
authors.forename: David M
authors.initials: DM
authors.lastname: Goldenberg
authors.forename: Edmund A
authors.initials: EA
authors.lastname: Rossi
authors.forename: Rhona
authors.initials: R
authors.lastname: Stein
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Cardillo
authors.forename: Myron S
authors.initials: MS
authors.lastname: Czuczman
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Hernandez-Ilizaliturri
authors.forename: Hans J
authors.initials: HJ
authors.lastname: Hansen
authors.forename: Chien-Hsing
authors.initials: CH
authors.lastname: Chang
mesh_terms: D019943:Amino Acid Substitution; D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000235:genetics / Q000276:immunology*; D000970:Antineoplastic Agents / Q000276:immunology* / Q000494:pharmacology; D001402:B-Lymphocytes / Q000276:immunology; D045744:Cell Line, Tumor; D002522:Chlorocebus aethiops; D003165:Complement System Proteins / Q000235:genetics / Q000276:immunology; D022801:Complementarity Determining Regions / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D004195:Disease Models, Animal; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D051379:Mice; D020125:Mutation, Missense; D000069283:Rituximab; D013329:Structure-Activity Relationship
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D022801:Complementarity Determining Regions; C448700:epratuzumab; D000069283:Rituximab; D003165:Complement System Proteins